A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

NCT03679767 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

121

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Non-small Cell Lung Cancer
Locally Advanced Urothelial Cancer
Metastatic Urothelial Cancer
Unresectable Melanoma
Metastatic Melanoma
Locally Advanced Renal Cell Carcinoma
Metastatic Clear-Cell Renal Cell Carcinoma

Interventions

DRUG: Retifanlimab

Sponsor

Incyte Corporation